- Home
- ARWR
as 03-28-2025 4:00pm EST
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | PASADENA |
| Market Cap: | 2.5B | IPO Year: | 1993 |
| Target Price: | $41.44 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.15 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.66 - $30.41 | Next Earning Date: | 05-08-2025 |
| Revenue: | $2,500,000 | Revenue Growth: | -98.62% |
| Revenue Growth (this year): | 4380.43% | Revenue Growth (next year): | 59.62% |
Stock Insider Trading Activity of Arrowhead Pharmaceuticals Inc. (ARWR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Anzalone Christopher Richard | ARWR | Chief Executive Officer | Mar 13 '25 | Sell | $15.07 | 51,425 | $774,974.75 | 4,062,377 | |
| Anzalone Christopher Richard | ARWR | Chief Executive Officer | Mar 3 '25 | Sell | $17.53 | 300,000 | $5,274,333.67 | 4,062,377 | |
| OLUKOTUN ADEOYE Y | ARWR | Director | Jan 23 '25 | Sell | $21.00 | 959 | $20,139.00 | 35,781 | |
| Hamilton James C | ARWR | Chief Discovery/Trans Medicine | Jan 4 '25 | Sell | $19.90 | 32,729 | $648,824.25 | 283,093 | |
| O'Brien Patrick | ARWR | COO and General Counsel | Jan 4 '25 | Sell | $19.83 | 37,184 | $736,058.62 | 544,727 | |
| Myszkowski Kenneth Allen | ARWR | Chief Financial Officer | Jan 4 '25 | Sell | $19.79 | 45,167 | $893,095.40 | 482,835 | |
| Anzalone Christopher Richard | ARWR | Chief Executive Officer | Jan 2 '25 | Sell | $19.05 | 11,520 | $219,456.00 | 4,062,377 |
Latest Arrowhead Pharmaceuticals Inc. News
ARWR Breaking Stock News: Dive into ARWR Ticker-Specific Updates for Smart Investing
Argus Research
4 days ago
ARWR: Rating increased to a HOLD
Simply Wall St.
4 days ago
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is favoured by institutional owners who hold 70% of the company
MT Newswires
12 days ago
Arrowhead Pharmaceuticals Insider Sold Shares Worth $774,975, According to a Recent SEC Filing
Benzinga
19 days ago
Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases
MT Newswires
19 days ago
Arrowhead Pharmaceuticals Says Study for Complement-Mediated Disease Therapy Shows C3 Reduction in Patients
Business Wire
19 days ago
Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy
MT Newswires
23 days ago
Arrowhead Pharmaceuticals Presents Data on Two Clinical-Stage Candidates for Obesity Treatment
Business Wire
23 days ago
Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases
Compare ARWR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARWR Arrowhead Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.